A piece of news
Biocat attended the most important event for the international biotechnology sector to raise awareness of the assets and main projects in the BioRegion through meetings with various international investment funds and corporates.
BIO International Convention 2022 once again saw record turnout. Over 3,400 companies attended the most important partnering event in the international biotechnology sector, held 13 to 16 June in San Diego, California, United States. After the latest edition marked by COVID-19, at the inaugural presentation, one of the representatives of the Biotechnology Innovation Organization highlighted the important role science has played in recent years: “We’re all here again, face-to-face, thanks to biotechnology,” he stressed.
Drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell technology were the main topics of this international event where Biocat, represented by Biocat CEO Robert Fabregat and Director of Science Policy and Internationalization Montse Daban, raised awareness of the assets and main projects in the BioRegion through over 20 meetings with various international investors and corporates.
“The 56 therapies being developed that make up the BioRegion pipeline, as well as the Catalan digital health startups, were the assets that interest from investment funds and corporates at the event,” explained Robert Fabregat. And it’s no surprise, because digital health hasn’t stopped growing in number of companies or investment, nearly doubling the figure from the previous year with over €60 million, according to the 2021 BioRegion Report.
Biocat also saw the growing attractiveness of the BioRegion at an extremely advantageous and dynamic fair where, despite being a biotechnology event, digital health has gained ground and the sector’s sustainability has become one of the main topics of interest.
Apart from the partnering meetings, Biocat also took advantage of BIO to meet with potential strategic partners. “We’ve initiated collaborations with entities in Mexico and Argentina and valued new opportunities in markets such as India and Japan,” highlighted Montse Daban, who advanced possible participations for the upcoming edition of BIO in Boston in 2023. They also analyzed the industry’s challenges in terms of European regulations with the heads of EuropaBIO.
The event was also used to promote BIOSPAIN 2023 among the European and international delegations, who showed great interest as it is being held in the Catalan capital at a time when Catalonia lead international rankings in number of startups, scientific publications and clinical trials.
Biocat and 25 companies and organizations from the BioRegion took part in this latest edition. Acellera LABS, Ahead Therapeutics, BCN Peptides, Cebiotex Biomedical Nanofiber, Connecta Therapeutics, Cytes Biotechnologies, Gebro Pharma, GP Pharm and Oryzon Genomics had stands in the Spanish pavilion, Salvat attended with its own booth, and Ability Pharma, ADmit Therapeutics and ZeClinics were present in the European pavilion.
Other companies and organizations from the BioRegion that attended include Almirall, ACIL Biopharm, ESTEVE, Ferrer Internacional, Grifols, Intas Pharmaceutical, Laboratorios Farmacéuticos ROVI, Laboratorios Rubió, Trifermed, Universitat Autònoma de Barcelona, and Werfen.